Filing Details
- Accession Number:
- 0001209191-20-054213
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-07 18:40:32
- Reporting Period:
- 2020-10-05
- Accepted Time:
- 2020-10-07 18:40:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1769804 | Augmedix Inc. | NONE | Blank Checks (6770) | 833299164 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1826030 | Jason Krikorian | C/O Augmedix, Inc. 1161 Mission Street, Suite 210 San Francisco CA 94103 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-10-05 | 3,064,751 | $0.00 | 3,064,751 | No | 4 | A | Indirect | See footnote |
Common Stock | Acquisiton | 2020-10-05 | 666,667 | $3.00 | 3,731,418 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2020-10-05 | 20,007 | $0.00 | 20,007 | No | 4 | A | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
No | 4 | A | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrant (right to buy) | Acquisiton | 2020-10-05 | 269,490 | $0.00 | 269,490 | $2.88 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
269,490 | 2029-09-02 | No | 4 | A | Indirect |
Footnotes
- On October 5, 2020, the Issuer's wholly-owned subsidiary, August Acquisition Corp. ("Acquisition Sub"), merged with and into Augmedix, Inc., a privately held Delaware corporation ("Augmedix"). Pursuant to this transaction (the "Merger"), Augmedix was the surviving corporation and became the Issuer's wholly owned subsidiary. All of the outstanding shares of stock of Augmedix held by accredited investors were converted into shares of the Issuer's common stock. All of the outstanding warrants, options and stock appreciation rights of Augmedix were assumed by the Issuer.
- These securities are held of record by DCM VI, L.P. ("DCM VI"). The Reporting Person, a member of our board of directors, is a general partnerat DCM, which is an affiliate of DCM VI. The Reporting Person disclaims beneficial ownership of these securities except to the extent of hispecuniary interest therein, if any.
- These securities are held of record by A-Fund, L.P. ("A-Fund"). The Reporting Person, a member of our board of directors, is a general partnerat DCM, which is an affiliate of A-Fund. The Reporting Person disclaims beneficial ownership of these securities except to the extent of hispecuniary interest therein, if any.
- The warrants are fully vested and exerciseable.